Abstracts tagged "Rheumatoid arthritis (RA)"

Abstract Number: 545 • 2019 ACR/ARP Annual Meeting
Molecular Analysis of the Mode of Action of Upadacitinib in Rheumatoid Arthritis Patients: Whole Blood RNA Expression Data from the SELECT-NEXT Study
Samantha Lent ¹, Thierry Sornasse ², Robert Georgantas ¹, Jeremy Sokolove ² and Iain McInnes³, ¹AbbVie, Inc., North Chicago, IL, ²AbbVie Immunology Clinical Development, Redwood City, ³Institute of Infection, Immunity & Inflammation, University of Glasgow, Glasgow, United Kingdom
Background/Purpose: Upadacitinib (UPA), an oral JAK inhibitor selective for JAK1, demonstrated efficacy in patients with moderate-to-severe rheumatoid arthritis (RA) with an inadequate response to conventional…
Abstract Number: 847 • 2019 ACR/ARP Annual Meeting
Safety Profile of Baricitinib for the Treatment of Rheumatoid Arthritis up to 7 Years: An Updated Integrated Safety Analysis
Mark Genovese¹, Josef Smolen ², Tsutomu Takeuchi ³, Gerd Burmester ⁴, Dennis Brinker ⁵, Terence Rooney ⁵, Jinglin Zhong ⁶, Daojun Mo ⁵, Chadi Saifan ⁵, Anabela Cardoso ⁵, Maher Issa ⁵, Wen-Shuo Wu ⁵ and Kevin Winthrop ⁷, ¹Stanford University, Stanford, CA, ²Medical University of Vienna, Vienna, Austria, ³Keio University School of Medicine, Tokyo, Japan, ⁴Charité—University Medicine Berlin, Berlin, Germany, ⁵Eli Lilly and Company, Indianapolis, IN, ⁶IQVIA, Morrisville, NC, ⁷Oregon Health and Science University, Portland, OR
Background/Purpose: Baricitinib (bari), an oral, selective inhibitor of Janus kinase (JAK) 1 and 2, is used to treat moderately to severely active RA in adults.…
Abstract Number: 980 • 2019 ACR/ARP Annual Meeting
Sema3B Expression Is Reduced in Rheumatoid Arthritis Patients and Has a Protective Role in a Murine Model of Arthritis
Ana Igea ¹, Tiago Carvalheiro ², Beatriz Malvar Fernandez ², Angela Rodriguez-Trillo ³, Trudy McGarry ⁴, Carmen Conde ⁵, Douglas Veale ⁶, Ursula Fearon ⁷, Africa Gonzalez ¹, Timothy R.D. Radstake ⁸, Kris A. Reedquist ² and Samuel Garcia⁹, ¹Department of Immunology, Centro de Investigaciones Biomédicas (CINBIO), Centro de Investigación Singular de Galicia, Instituto de Investigación Sanitaria Galicia Sur, Universidad de Vigo, Vigo, Spain, ²Department of Rheumatology and Clinical Immunology and Laboratory of Translational Immunology, University Medical Center Utrecht, University of Utrecht, Utrecht, Netherlands, ³laboratorio de Reumatología Experimental y Observacional, Instituto de Investigación Sanitaria de Santiago (IDIS)-Hospital Clinico (CHUS), Santiago de Compostela, Spain, ⁴Department of Molecular Rheumatology, Trinity Biomedical Science Institute, Trinity College Dublin, Dublin, Ireland, ⁵Laboratorio de Reumatología Experimental y Observacional, y Servicio de Reumatología, Instituto de Investigacion Sanitaria de Santiago (IDIS), Hospital Clínico Universitario de Santiago de Compostela (CHUS), SERGAS, Santiago de Compostela, Spain, ⁶EULAR Centre For Arthritis And Rheumatic Diseases and The Conway Institute, Dublin, Ireland, ⁷Molecular Rheumatology, Trinity Biomedical Sciences Institute, TCD, Dublin, Ireland, ⁸Department of Rheumatology/Clinical Immunology, University Medical Center Utrecht, Utrecht, The Netherlands., Utrecht, Netherlands, ⁹Department of Rheumatology and Clinical Immunology, University Medical Center Utrecht, University of Utrecht, Utrecht, Spain
Background/Purpose: The semaphorin family is a large group of proteins initially described in axon guidance. However, semaphorins also play a role in other processes involved…
Abstract Number: 1184 • 2019 ACR/ARP Annual Meeting
Rheumatoid Arthritis Activity Assessment with Cellphone Thermal Camera Imaging Compared to Clinical and Ultrasound Assessments
Caroline Paris ¹, Pierre Lafforgue ¹, Vincent Pradel ², Christophe Richez ³ and Thao Pham¹, ¹Aix-Marseille University, CHU Marseille, department of Rheumatology, 13,000 Marseille, France, Marseille, France, ²APHM -Assistance publique des hôpitaux de Marseille, Marseille, Finland, ³Pellegrin Hospital, University Hospital of Bordeaux, Bordeaux, France
Background/Purpose: The assessment of active joints is a core component of widely used outcome measures in rheumatoid arthritis (RA). However, variability exists within and across…
Abstract Number: 1347 • 2019 ACR/ARP Annual Meeting
Achievement of Remission in Two Early Rheumatoid Arthritis Cohorts Implementing Different Treat-To-Target Strategies
Vibeke Norvang¹, Gina Hetland Brinkmann ², Kazuki Yoshida ³, Siri Lillegraven ⁴, Anna-Birgitte Aga ⁵, Joe Sexton ⁴, Sara K. Tedeschi ⁶, Till Uhlig ¹, Tore Kvien ¹, Maria Dahl Mjaavatten ⁴, Daniel Solomon ⁷, Espen Haavardsholm ¹ and Houchen Lyu ⁸, ¹Diakonhjemmet Hospital, Dept. of Rheumatology / University of Oslo, Faculty of Medicine, Oslo, Norway, ²Østfold Hospital Trust, Dept. of Rheumatology, Grålum, Norway, ³Brigham and Women's Hospital, Div. of Rheumatology, Immunology and Allergy, Boston, ⁴Diakonhjemmet Hospital, Dept. of Rheumatology, Oslo, Norway, ⁵Diakonhjemmet Hospital, Department of Rheumatology, Oslo, Oslo, Norway, ⁶Brigham and Women's Hospital, Div. of Rheumatology, Immunology and Allergy, Boston, MA, ⁷Brigham and Women´s Hospital, Div. of Rheumatology, Immunology and Allergy, Boston, MA, ⁸Brigham and Women´s Hospital, Div. of Rheumatology, Immunology and Allergy, Boston
Background/Purpose: A treat-to-target (TTT) approach results in superior outcomes compared to conventional care in patients with rheumatoid arthritis (RA). However, TTT strategies are still not…
Abstract Number: 1377 • 2019 ACR/ARP Annual Meeting
MTX Withdrawal in Patients with RA Who Achieve Low Disease Activity with Tofacitinib Modified-Release 11 Mg Once Daily + MTX: An Assessment of the Impact on the Short Form-36 Patient-Reported Outcome
Vibeke Strand¹, Janet Pope ², John Woolcott ³, Jose L. Rivas ⁴, Annette Diehl ³, Shixue Liu ⁵, David Gruben ⁶ and Stanley Cohen ⁷, ¹Division of Immunology/Rheumatology, Stanford University, Palo Alto, CA, ²Western University, London, ON, Canada, ³Pfizer Inc, Collegeville, PA, ⁴Pfizer SLU, Madrid, Spain, ⁵Pfizer Inc, Shanghai, China (People's Republic), ⁶Pfizer Inc, Groton, CT, ⁷Metroplex Clinical Research Center, Dallas, TX
Background/Purpose: Tofacitinib is an oral Janus kinase inhibitor for the treatment of RA. Tofacitinib +/- background MTX has been shown to be an effective treatment…
Abstract Number: 1410 • 2019 ACR/ARP Annual Meeting
Cycling of Tumor Necrosis Factor-α (TNF-α) Inhibitors versus Switching to Different Μechanism of Αction in Rheumatoid Arthritis Patients with Inadequate Response to TNF-α Inhibitor: A Bayesian Network Meta-analysis
Alberto Migliore¹, Giuseppe Pompilio ², Davide Integlia ², Joe Zhuo ³ and Evo Alemao ⁴, ¹Unit of Rheumatology Ospedale S. Pietro Fatebenefratelli, Rome, Italy, ²Isheo Srl, Rome, Italy, ³Bristol-Myers Squibb, Princeton, NJ, ⁴Bristol-Myers Squibb, Princeton
Background/Purpose: TNF inhibitors are a common treatment for rheumatoid arthritis (RA), but there is no best practice for when a specific TNF inhibitor stops working1.…
Abstract Number: 1445 • 2019 ACR/ARP Annual Meeting
Pre-Biologic Use of Janus Kinase Inhibitors for the Treatment of Rheumatoid Arthritis in the United States
Lynn Price¹, Phil Pouliot ¹ and Lauren Schmitt ¹, ¹Spherix Global Insights, Exton, PA
Background/Purpose: Tofacitinib was the first Janus kinase (JAK) inhibitor FDA approved for the treatment of RA in November 2012, five- and one-half years later, baricitinib,…
Abstract Number: 1892 • 2019 ACR/ARP Annual Meeting
Association Between Rheumatoid Arthritis Treatment and the Risk of Death or Readmission After Major Surgery
Michael George¹, Joshua Baker ², Kevin Winthrop ³, Lang Chen ⁴, Qufei Wu ², Fenglong Xie ⁵ and Jeffrey Curtis ⁴, ¹University of Pennsylvania, Philadelphia, ²University of Pennsylvania, Philadelphia, PA, ³Oregon Health and Science University, Portland, OR, ⁴University of Alabama at Birmingham, Birmingham, AL, ⁵University of Alabama at Birmingham, Birmingham
Background/Purpose: The impact of immunosuppression on post-operative outcomes in rheumatoid arthritis (RA) has primarily been studied in patients undergoing joint replacement surgery. We aimed to…
Abstract Number: 2011 • 2019 ACR/ARP Annual Meeting
Novel Somatic Mutations Identified by Whole Genome Sequencing of Rheumatoid Arthritis (RA) Fibroblast-Like Synoviocytes (FLS)
Richard Ainsworth ¹, Deepa Hammaker ², David Boyle ¹, Rizi Ai², Jeremy Sokolove ³, Wei Wang ¹ and Gary Firestein ², ¹University of California, San Diego, San Diego, CA, ²University of California, San Diego, San Diego, ³AbbVie Immunology Clinical Development, Redwood City
Background/Purpose: Somatic mutations caused by reactive oxygen and nitrogen species in inflamed joints, have been implicated in the destructive nature of RA. Mutation analysis also…
Abstract Number: 2209 • 2019 ACR/ARP Annual Meeting
Study of Vertebral Fracture Prevalence and Scanographic Bone Attenuation Coefficient of the First Lumbar Vertebra (SBAC-L1) in Patients with Rheumatoid Arthritis and Ankylosing Spondylitis vs. Controls
Marine Fauny¹, Eliane Albuisson ², Elodie Bauer ¹, Julia Perrier-Cornet ¹, Isabelle Chary-Valckenaere ² and Damien Loeuille ³, ¹CHRU Nancy, VANDOEUVRE, France, ²Centre Hospitalier Universitaire de Nancy, VANDOEUVRE, France, ³Rheumatology, Nancy University Hospital and and UMR 7365 CNRS-UL IMoPA, Université de Lorraine, VANDOEUVRE, France
Background/Purpose: Osteoporosis is a common disease whose prognosis can be seriously impacted by the development of fractures that lead to functional limitations and may even…
Abstract Number: 2305 • 2019 ACR/ARP Annual Meeting
Multimorbidity May Worsen Fatigue in Patients with Rheumatoid Arthritis
John Davis¹, Elena Myasoedova ¹, Tina Gunderson ¹ and Cynthia Crowson ², ¹Mayo Clinic, Rochester, MN, ²Mayo Clinic Rochester, Rochester
Background/Purpose: Fatigue is a pervasive problem for many patients with rheumatoid arthritis (RA) that often persists despite treatment with effective disease-modifying therapies. Recent studies have…
Abstract Number: 2326 • 2019 ACR/ARP Annual Meeting
Prognostic Markers for Preclinical Cardiovascular Disease in Rheumatoid Arthritis and Correlation with Disease Activity
Annelies Blanken¹, Rabia Agca ², Conny van der Laken ³ and Mike Nurmohamed ⁴, ¹Amsterdam Rheumatology and immunulogy Center location Reade, Amsterdam, Netherlands, ²Amsterdam Rheumatology and immunology Center location Reade, Amsterdam, Netherlands, ³Amsterdam Rheumatology and immunology Center location Amsterdam UMC location VU medical center, Amsterdam, Netherlands Antilles, ⁴Amsterdam Rheumatology and immunology Center location Reade and Amsterdam UMC location VU medical center, Amsterdam, Netherlands
Background/Purpose: Patients with rheumatoid arthritis (RA) have an elevated cardiovascular (CV) disease risk, explained both by an increased prevalence of traditional CV risk factors and…
Abstract Number: 2344 • 2019 ACR/ARP Annual Meeting
Efficacy of Mycophenolate Mofetil in the Treatment of Rheumatoid Arthritis Associated Interstitial Lung Disease
Jonathan Amos¹, Jennifer Kendall ¹, Robyn Moran ², Megan Krause ³, Paul Schmidt ⁴, Chase Hall ⁵, Mark Hamblin ⁶ and Mehrdad Maz ⁷, ¹University of Kansas Medical Center, Division of Rheumatology, KANSAS CITY, KS, ²University of Kansas Medical Center, Kansas City, KS, ³University of Kansas, KANSAS CITY, KS, ⁴University of Kansas Medical Center, Division of Rheumatology, Kansas City, ⁵University of Kansas Medical Center, Division of Pulmonary and Critical Care, KANSAS CITY, ⁶University of Kansas Medical Center, Division of Pulmonary and Critical Care, Kansas City, KS, ⁷The University of Kansas Medical Center, KANSAS CITY, KS
Background/Purpose: Interstitial lung disease (ILD) as an extra-articular manifestation of rheumatoid arthritis (RA) leads to significant morbidity and mortality. As data is limited, this study…
Abstract Number: 2372 • 2019 ACR/ARP Annual Meeting
Post-Approval Comparative Safety Study of Tofacitinib and Biologic DMARDs: Five‑Year Results from a US-based Rheumatoid Arthritis Registry
Joel Kremer¹, Clifton Bingham ², Laura Cappelli ², Jeffrey Greenberg ³, Jamie Geier ⁴, Ann Madsen ⁴, Connie Chen ⁴, Alina Onofrei ⁵, Christine Barr ⁵, Dimitrios Pappas ⁶, Heather Litman ⁵, Kimberly Dandreo ⁵, Andrea Shapiro ⁷, Carol Connell ⁸ and Arthur Kavanaugh ⁹, ¹Albany Medical College, Albany, NY, ²Johns Hopkins University, Baltimore, MD, ³Corrona, LLC; NYU School of Medicine, Waltham, MA, ⁴Pfizer Inc, New York, NY, ⁵Corrona, LLC, Waltham, MA, ⁶Columbia University, New York, NY, ⁷Pfizer Inc, Peapack, NJ, ⁸Pfizer Inc, Groton, CT, ⁹University of California, San Diego School of Medicine, La Jolla, CA
Background/Purpose: Tofacitinib is an oral JAK inhibitor for the treatment of RA. Real‑world data (RWD) complement clinical trial data in assessing long-term safety. We evaluated…

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM ET on November 14, 2024. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].